COVID-19 Records

Transcript segment

Baric Transcribed Interview (Redacted), p.119 · baric_ti:utt:01024

Page text: p.119 · original PDF

Date
2026-04-10 09:00 (day precision)
Type
transcript segment · interview
recipient
Ralph S. Baric, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
speaker
Christina Salazar
Okay. And how much are shipping costs?

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

  1. 2026-04-10 09:00 Christina Salazar open
    Is it typical that the transmittal fee would be zero? I just don't know.
  2. 2026-04-10 09:00 Ralph S. Baric open
    It depends on how much money I would have.
  3. 2026-04-10 09:00 Christina Salazar open
    Okay. Like what does that range sometimes look like?
  4. 2026-04-10 09:00 Ralph S. Baric open
    Whatever the shipping cost are. DC.Scheduling@LexitasLegal.com
  5. 2026-04-10 09:00 Christina Salazar
    Okay. And how much are shipping costs?
  6. 2026-04-10 09:00 Ralph S. Baric open
    You know, I haven't shipped anything. I have somebody else I have to do it. We have a person who's trained as a shipper, and they take care of it.
  7. 2026-04-10 09:00 Christina Salazar open
    Okay. I want to go back to the DARPA question on PREEMPT. I'll show you this email, and I don't have another copy of it right now. But it is dated March 7, 2019. It's from Vineet Menarchery, and you have a couple of other folks on here from Autonomous Therapeutics. [Exhibit No. 3 shown.]
  8. 2026-04-10 09:00 Christina Salazar open
    It says, "Ralph, I've been working on a DARPA proposal with Autonomous Therapeutics on MERS-CoV with a quick turnaround. They're funded for another DARPA project to generate therapeutic interfering particles, and are looking to apply their approach for MERS on this specific supplement call. We have been chatting for a few weeks, and they are interested in both in vitro and in vivo experiments with their MERS-CoV targeted TIPs. I am currently planning to work with them on the in vitro side, but suggest they talk directly to you about the DPPR 288/330 model."
  9. 2026-04-10 09:00 Ralph S. Baric open
    Okay.

Full conversation →